NEW BRUNSWICK (dpa-AFX) - Shares of Rallybio Corp. (RLYB) are up 71% on
Thursday following the announcement of a partnership with Johnson & Johnson
(JNJ) aimed at advancing therapeutic approaches to mitigate the risk of fetal
and neonatal alloimmune thrombocytopenia also known as FNAIT.

RLYB is trading on the Nasdaq at $2.79, up 71.47% or $1.16 per share. It has
traded between $1.22 and $9.14 in the past 52-week period.

Additionally, Rallybio secured a $6.6 million equity investment from Johnson &
Johnson Innovation.

The company is working on RLYB212, a human monoclonal anti-HPA-1a antibody
designed to prevent FNAIT by halting the production of alloantibodies in
expecting mothers.

Rallybio intends to commence a Phase 2 trial for RLYB212 in the latter part of
2024.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX